Blood and Lymph Conditions

Diseases and Abnormalities at or Before Birth

All Conditions

Nutritional and Metabolic Diseases

Rare Diseases

Anemia, Sickle Cell

Thalassemia

Iron Overload

Hemochromatosis

Hemosiderosis

Metabolic Diseases

Iron Metabolism Disorders

Sickle Cell Anemia

Hemochromatosis Type 3

Micronutrients

All Drugs and Chemicals

Hematinics

Iron

Liver Extracts

Patients with iron overload or excessive body iron burden, a serious condition resulting from increased dietary gastro¬intestinal absorption, multiple erythrocyte transfusions, or both.

Interventions: R2\*-UTE, R2\*-GRE, and if clinically indicated, liver biopsy.

Ultra short echo time (UTE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2\*-UTE scans will be performed.

R2*-UTE

Gradient-echo (GRE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2\*-UTE scans will be performed.

R2*-GRE

Indications for liver biopsy include, but are not limited, to the need to quantify liver tissue iron and the need to obtain histopathological information of the liver tissue. Liver biopsies will only be performed if clinically indicated and will be done only once per patient. The technique to be used is coaxial percutaneous (transcapsular) technique; however, a coaxial transjugular technique may be performed in subjects with increased bleeding diathesis, since it is associated with less hemorrhagic risk. Healthy volunteers will not undergo liver biopsy.

Liver biopsy

Jane Hankins, MD, MS

Iron overload is a severe complication of multiple blood transfusions. As the body has no physiologic mechanism for clearing iron, repeated transfusions cause iron accumulation in organs and lead to iron toxicity. Accurate assessment of iron overload is paramount to quantify excessive iron accumulation and to monitor response to iron chelation therapy. Magnetic resonance imaging (MRI) methods have been used to noninvasively measure hepatic iron concentration (HIC). Although MRI-based measurements of transverse relaxation rates (R2 and R2\*) accurately predict biopsy-proven HICs below 15 mg Fe/g, previous studies have shown that their precision is limited for HICs above 15 mg Fe/g and inaccurate above 25 mg Fe/g. Current R2\* gradient-echo (GRE) MR techniques fail occasionally for very high iron overloads (HIC \~ 15-25 mg Fe/g) and always for massive iron overloads (HIC \> 25 mg Fe/g) because R2\* is so high that the MR signal decays before it can be measured accurately.

Overall accrual: 200 patients

Purpose: To determine if a new MRI (UTE) can measure the amount of iron in the liver of people with large amounts of iron and compare the results with the same patient's liver bx. Estimated patient accrual is 150. It is estimated that 41 of these patients will have clinical indication for liver biopsy.

The MIDAS study is a prospective and non-therapeutic study that will test a new MRI technique for the assessment of iron overload in the liver: the newly developed ultra short echo time (UTE), R2\*-UTE. The R2\*-UTE technique, developed by St. Jude investigators from the Department of Radiological Sciences, will be first tested in healthy volunteers for feasibility and implementation of the technique. The technique will then be tested in research participants, who will have both the R2\*-GRE and the R2\*-UTE techniques performed, in addition to a liver biopsy for liver iron quantitation if clinically indicated. Quantitation of liver tissue iron will be done at Mayo Clinic Laboratory in Rochester, Minnesota.

Primary Objective:

* To test the association of hepatic iron content (HIC) measured with the newly developed 1.5T R2\*-UTE technique and HIC quantified by liver biopsy in subjects with iron overload.

Secondary Objectives:

* To explore the relationship between 1.5T R2\*-UTE and 1.5T R2\*-GRE measurements in subjects with iron overload.
* To explore the relationship between 1.5T R2\*-UTE measurements with iron studies (serum iron and transferrin saturation) in subjects with iron.

Massive Iron Deposit Assessment

Hepatic iron content in the liver using liver biopsy

Hepatic iron content of the liver using MRI-derived 1.5T R2\*-UTE measurement, with results in Hz. R2\* is a measure obtained with MRI, i.e., MRI R2\*. It is measured in hertz (Hz). In lay terms, the MRI machine picks up a signal back from the tissue during the process of scanning the tissues. With every "picture taken", this signal is strong in the beginning and then wanes off. R2\* reflects how fast the signal wanes off. If there is too much iron in the tissue, the signal disappears faster, making the T2\* value low. T2\* is the reciprocal of R2\* (R2\*= 1/T2\*). So, if the signal drops fast, the T2\* is low and the R2\* is high. In this study, we are measuring the R2\* value. The higher the R2\*, the more iron in the liver tissue. We can compare the R2\* value with that of a liver biopsy to then use the R2\* value to tell us how much iron is in the liver without having to biopsy the liver.

MRI-derived R2\* Using 1.5T GRE Technique in Hz. R2\* is a measure obtained with MRI, i.e., MRI R2\*. It is measured in hertz (Hz). In lay terms, the MRI machine picks up a signal back from the tissue during the process of scanning the tissues. With every "picture taken", this signal is strong in the beginning and then wanes off. R2\* reflects how fast the signal wanes off. If there is too much iron in the tissue, the signal disappears faster, making the T2\* value low. T2\* is the reciprocal of R2\* (R2\*= 1/T2\*). So, if the signal drops fast, the T2\* is low and the R2\* is high. In this study, we are measuring the R2\* value. The higher the R2\*, the more iron in the liver tissue. We can compare the R2\* value with that of a liver biopsy to then use the R2\* value to tell us how much iron is in the liver without having to biopsy the liver.

MRI-derived R2\* value using 1.5T R2\*-UTE in Hz. R2\* is a measure obtained with MRI, i.e., MRI R2\*. It is measured in hertz (Hz). In lay terms, the MRI machine picks up a signal back from the tissue during the process of scanning the tissues. With every "picture taken", this signal is strong in the beginning and then wanes off. R2\* reflects how fast the signal wanes off. If there is too much iron in the tissue, the signal disappears faster, making the T2\* value low. T2\* is the reciprocal of R2\* (R2\*= 1/T2\*). So, if the signal drops fast, the T2\* is low and the R2\* is high. In this study, we are measuring the R2\* value. The higher the R2\*, the more iron in the liver tissue. We can compare the R2\* value with that of a liver biopsy to then use the R2\* value to tell us how much iron is in the liver without having to biopsy the liver.

MRI-derived R2\* value using 1.5T R2\*-UTE in Hz for patients who have had serum iron and transferrin saturation measurements. R2\* is a measure obtained with MRI, i.e., MRI R2\*. It is measured in hertz (Hz). In lay terms, the MRI machine picks up a signal back from the tissue during the process of scanning the tissues. With every "picture taken", this signal is strong in the beginning and then wanes off. R2\* reflects how fast the signal wanes off. If there is too much iron in the tissue, the signal disappears faster, making the T2\* value low. T2\* is the reciprocal of R2\* (R2\*= 1/T2\*). So, if the signal drops fast, the T2\* is low and the R2\* is high. In this study, we are measuring the R2\* value. The higher the R2\*, the more iron in the liver tissue. We can compare the R2\* value with that of a liver biopsy to then use the R2\* value to tell us how much iron is in the liver without having to biopsy the liver.

Serum iron measurements from eligible patients had 1.5T R2\*-UTE and serum iron and transferrin saturation measurements.

Iron Transferrin Saturation in % measurements Transferrin Saturation measurements from eligible patients had 1.5T R2\*-UTE and serum iron and transferrin saturation measurements.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Regional One Health

St. Jude Children's Research Hospital

Eligible iron-overloaded patients with both liver biopsy measurement and 1.5T R2\*-UTE measurement

Iron-overloaded Patients

All eligible patients with history of 12 or more lifetime erythrocyte transfusions, and need for liver iron content assessment

Arm 1

Age, Categorical

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

Asian

Black or African American

White

More than one race

Unknown or Not Reported

Race/Ethnicity, Customized

United States

Region of Enrollment

Jane Hankins, MD

Eligible iron-overloaded patients with both liver biopsy measurement and 1.5T R2\*-UTE measurement.

Hepatic Iron Content in the Liver Using Liver Biopsy

MRI-derived R2* Values Using 1.5T UTE Technique

Iron-overloaded patients defined as having more than 12 transfusions in their lifetime as measured with R2\* using 1.5T GRE.

Iron-overloaded patients had 1.5T R2\*-GRE measurements.

MRI-derived R2* Using 1.5T GRE Technique

Iron-overloaded patients with R2\* using 1.5T UTE

Iron-overloaded patients had 1.5T R2\*-UTE-measurement.

MRI Derived R2* Using 1.5T UTE Technique

1.5T R2\*-UTE from eligible patients who had 1.5T R2\*-UTE, serum iron, and transferrin saturation measurements.

R2* Using 1.5T UTE Technique for Patients With Serum Iron and Transferrin Saturation Measurements

Serum Iron Measurements

Iron-overloaded patients had 1.5T R2\*-UTE and serum iron and transferrin saturation measurements.

Serum Iron Measurements Compared With 1.5T R2* UTE

Iron-overloaded patients with 1.5T R2\*-UTE and serum iron and transferrin saturation measurements.

Transferrin Saturation Measurements

All eligible patients with history of 12 or more lifetime erythrocyte transfusions, and need for liver iron content assessment.

Overall Study

Symptoms and General Pathology

Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

Occupational Diseases

Syndrome

Preleukemia

Myelodysplastic Syndromes

Siderosis

Bone Marrow Diseases

Hematologic Diseases

Precancerous Conditions

Metabolism, Inborn Errors

Metal Metabolism, Inborn Errors

Genetic Diseases, Inborn

Pharmaceutical Solutions

Deferasirox

Chelating Agents

Iron Chelating Agents

10 patients with hemochromatosis treated with Deferasirox

10 patients with hemochromatosis treated with venesection

20 patients with myelodysplastic syndrome treated with Deferasirox

10 healthy control persons to assess the normal level of investigational blood tests.

Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months

Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.

Venesection

Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.

Rune J Ulvik, MD, PhD

Hypothesis: Deferasirox can be used as a therapeutic agent to deplete the liver, heart and bone marrow of excess iron in patients with iron overload caused by myelodysplastic syndrome (MDS) and hemochromatosis (HC.

Assess the effect of new serum biomarkers (NTBI and hepcidin) and MRI as indicators of iron overload and their usefulness to monitor iron depletion treatment.

Study the effect of iron overload and iron depletion on intracellular signal transduction, trace metals concentrations in serum and urine and markers of oxidative stress in blood cells and urine.

The two most important causes of iron overload disease in humans are the iron-loading disorder hereditary hemochromatosis (HC), and transfusional siderosis in patients with chronic hematological diseases like myelodysplastic syndrome (MDS), thalassemia, and leukemia.

Hemochromatosis. In HC the molecular regulation of iron uptake across the intestinal mucosa is disturbed, leading to hyperabsorption and accumulation of iron in parenchymal tissues such as the liver, pancreas, endocrine organs and heart. Hepcidin, a small peptide hormone synthesized in the liver, apparently functions as the master regulator of systemic iron homeostasis by its ability to control the efflux of iron from the enterocytes and macrophages into blood plasma. This happens by diminishing the iron transfer capacity through the basolateral, transmembrane protein, ferroportin. Expression of hepcidin is carefully adjusted by the iron status of the hepatocytes through a multimolecular signal transducing pathway which acts as a positive feedback mechanism with increased hepcidin synthesis in iron overload (and inflammation). Mutation of one of the signal molecules, leads to inadequate hepcidin synthesis. The most common are the classic C282Y and H63D point mutations of the hemochromatosis protein HFE, which disturbs its interaction with the transferrin receptor 1, the first step in the hepcidin signal cascade. Homozygosity for C282Y is the strongest risk factor for serious iron overload and disease which develops after a long-lasting, asymptomatic period. In Norway the prevalence of C283Y homozygosity is approximately 0.75 in both genders. The preclinical, biochemical phenotype of HC is disclosed by blood tests with elevated transferrin saturation as a marker of hyperabsorption of iron, and increasing ferritin concentration as a surrogate marker of a growing iron overload. As an alternative to liver biopsy, magnetic resonance imaging (MRI) seems to be a powerful non-invasive method to directly assess the iron content of the liver and heart.

Myelodysplastic syndrome and transfusional siderosis. Transfusional iron overload is the result of multiple blood transfusions supplied over a long time period, each of which adds approximately 220 to 250 mg of extra iron to the body. Because iron loading occurs via a parenteral route with the macrophages as the primary target cells, the normal homeostatic mechanisms are not responding adequately and the plasma hepcidin level can be normal or even increased. Even if excess iron is better tolerated in macrophages than in parenchymal cells, a life-threatening iron overload develops much faster with transfusional siderosis than HFE-associated HC. Myelodysplastic syndrome (MDS) is a heterogeneous group of stem cell disorders with inefficient hematopoiesis and increased risk of developing acute myeloid leukemia. The MDS International Prognostic Scoring System (IPSS) which is based on numbers of cytopenias, cytogenetic features and number of blasts in the bone marrow, enables separation of four risk groups with the following median survival years: low-risk patients, 5.7 years; intermediate-1, 3.5 years; intermediate-2, 1.2 years; and high-risk 0.4 years. Many patients become transfusion-dependent and get serious transfusional iron overload. Iron chelation is recommended to low-risk and intermediate-1 patients with probable need of lifelong transfusion therapy.

Consequences of iron overload. If not interrupted, continuous iron loading will at some point start to gradually damage vital organs such as liver, heart and endocrine organs, and lead to serious disease and a shortened lifetime. At the molecular level persistently increased amounts of reactive, small molecular weight iron complexes or the sporadic presence of free iron in blood and tissues, are probably the fundamental pathogenetic mechanism in iron overload. These substances are highly toxic due to their strong ability to catalyze the formation of free radicals such as Reactive Oxygen Species (ROS). The activity of free radicals with damage of native molecules (e.g. DNA) and cellular structures is considered to be the first step in organ and tissue injury. In blood, reactive iron exists as Non-Transferrin Bound Iron (NTBI), mainly in the form of small molecular weight iron-citrate complexes. NTBI is rapidly taken up by the liver and other organs where it adds to the intracellular, reactive labile iron pool (LIP). The presence of NTBI and LIP has been found to correlate with hepatic and cardiac damage in transfusional siderosis and HC. In addition, the homeostasis of other trace metals may be abnormal in iron overload. Little is known about this issue, which warrants a deeper study.

Treatment. In HC, the preferred iron removal therapy is venesection, whilst transfusional iron overload is treated with iron chelators.

Clinical aims of study. The major objective is to determine the efficacy of deferasirox to remove iron from the liver, heart and bone marrow in HC- and MDS-patients with iron overload.

Explorative aims. Determine the correlation between the novel biomarkers hepcidin and NTBI, and ferritin and transferrin saturation in serum; and liver iron concentration (LIC), heart iron concentration (HIC), and bone marrow iron.

Assess the effect of iron overload and iron depletion with either deferasirox or venesection, on the concentration of trace metals in serum and urine in HC and MDS patients.

Study the influence of iron overload and iron depletion with either deferasirox or venesection, on intracellular signal transduction in blood cells isolated from HC and MDS patients.

Study the influence of iron overload and iron depletion with either deferasirox or venesection on oxidative damage of DNA (examined in urine), and the antioxidant status in red blood cells isolated from HC and MDS patients.

Establish reference values for the investigational serum and urine tests in healthy control subjects.

Rationale of the study. The major rationale of the study is related to the need to assess the potential use of deferasirox to treat HC- and MDS-patients with iron overload. However, several "learning objectives" are included: the impact of iron overload and iron depleting treatment on NTBI, hepcidin, markers of oxidative stress, trace metals and intracellular signal transduction molecules.

Although venesection is a safe and effective means of depleting iron in HC patients, it may suppress hepcidin and thus increase iron absorption, particularly at the end of a long treatment period. Also, some HC patients not only feel the cumbersome impact of frequent phlebotomies in daily life, but also experience troublesome side effects.

The subjective perception of venesection side effects was recently communicated in a survey study among 210 HC patients across the United States and some european countries. Of these, 52% of patients undergoing weekly venesections and 37% of the patients in the maintenance phase reported side effects "always" or "most of the time", and 16% would "definitely" or "probably" refuse phlebotomy if they were offered an alternative treatment. Therefore, investigation of the effect of chelator as a potential alternative therapy in HC is warranted. Chelation therapy may not only remove excess iron from the body, but may also counteract formation of reactive, free radicals.

In MDS patients transfusion dependency worsens the survival due to development of damaging iron overload. With every 500 ng/mL increase of s ferritin above the threshold, the risk of death increases by 30%.

Traditionally, iron depletion therapy has been monitored by s-ferritin, which decreases as iron is progressively eliminated. However, s-ferritin is a non-specific parameter which is sensitive to acute phase reactions associated with inflammations, chronic diseases and tissue injury. Furthermore, s-ferritin does not offer information about the burden of free radical production stimulated by reactive iron. For this reason, one aim of this study will be to investigate whether new blood markers like NTBI and hepcidin, along with MRI assessment of LIC and HIC, will improve the diagnosis of iron overload and more accurately identify those patients who are at increased risk of iron induced damage and therefore will benefit from iron depletion therapy.

Iron overload can weaken the cellular antioxidant defence and result in oxidative DNA-damage as the first step in carcinogenesis. Examination of the influence of iron overload and iron depletion with either deferasirox or venesection on oxidative damage of DNA, and on the antioxidant status in red blood cells will be performed.

Increased knowledge of how intracellular signal transduction is influenced by cellular iron and use of deferasirox may provide new insights into the molecular pathogenesis of iron overload. This will be examined in single leukocyte cell flowcytometry assays of the following intracelluar signal parameters: stress sensor p53, mTOR and NFkB.

Finally, little is known about how iron overload interacts with the metabolism of other trace metals. The concentration of a broad spectrum of trace metals in serum (S) and urine (U) will be monitored throughout the study period by Inductively Coupled Plasma Mass Spectrometry (ICP-MS) (28) : boron (S,U), barium (S,U), beryllium (S,U), cadmium (S,U), cobalt (S,U), cesium (S,U), copper (S,U), mercury (U), lithium (U), manganese (S), molybdenum (S), nickel (S,U), lead (S,U), antimony (S,U), selenium (S,U), tin (S,U), strontium (S,U), thallium (S,U), tungsten (S), yttrium (S,U), zinc (S,U).

The tolerability of deferasirox will also be assessed throughout the study, either as sole treatment in MDS patients or compared to venesection in HC patients.

Healthy volunteers are used solely as controls to determine the normal blood concentration of the biomarkers and tests which will be performed in the patients. The controls will not be treated.

Previous clinical trials in HC and MDS. Deferasirox has been studied in a variety of diseases with transfusional iron overload, particularly in thalassemia. It has a favorable profile with respect to efficacy, safety and tolerability. However, controlled clinical studies with deferasirox in HC and MDS are limited.

The study by Phatak et al (2010) was the first clinical trial to demonstrate the safety and efficacy of deferasirox in patients with C282Y-homzygot hemochromatosis. They showed that serum ferritin levels were reduced similarly in two cohorts given respectively 10 mg/kg/day and 15 mg/kg/day of deferasirox. Since the dose of 15 mg/kg/day caused a higher frequency of adverse events (AEs), they recommended a staring dose of 10 mg/kg/day to be most appropriate in HC- patients. The most important AEs were associated with an increase in serum creatinine and liver enzymes. The study was limited by pretreatment of some patients with phlebotomy prior to the deferasirox study; in addition, many of the patients had only mild iron overload. For this reason, we see no argument to use a higher dose in our study, and therefore we choose a starting deferasirox dose of 10 mg/kg/day in HC- patients.

In a recent study, 24 heavily transfused MDS patients were enrolled to receive 52 weeks of deferasirox therapy. Deferasirox was well tolerated and effectively reduced LIC, labile plasma iron and s-ferritin in patients completing 24 to 52 weeks of therapy, despite ongoing receipt of red blood cell transfusions. In addition to reducing long-term toxicity of iron overload, chelation therapy has shown beneficial effects on hematopoiesis in a small proportion of MDS patients. One ongoing study comparing deferasirox with placebo was found in Cochrane search carried out in June 2010.

Pharmacokinetics of deferasirox. Deferasirox (Exjade®) is a bivalent iron chelator which is taken orally as a tablet, once per day. It is readily absorbed and reaches peak concentration in blood after 1 to 2 hours. The half-life is 12 to 17 hours, and effective levels of active chelator are maintained in the blood for more than 24 hours. The drug is eliminated via the hepatobiliary system. The dose varies from 10 mg/kg/day in patients with mild iron overload to 30 mg/kg/day in patients with overt iron toxicity.

Adverse events (AEs) of deferasirox. The most frequent adverse clinical events are gastrointestinal disturbances and skin rash. The most frequent laboratory side effects are mild increase in serum creatinine and liver transaminases. The adverse events have for the most part been reported in patients with transfusional iron overload. In HC patients the data are more scarce due to the very few studies that have been performed in this group. Other common AEs include headache, constipation, abdominal distension, dyspepsia, pruritus, and proteinuria. Less common AEs include anxiety, sleep disorder, dizziness, early cataract, maculopathy, hearing loss, pharyngolaryngeal pain, gastrointestinal hemorrhage, gastric ulcer, duodenal ulcer, gastritis, oesophagitis, hepatitis, cholelithiasis, pigmentation disorder, renal tubulopathy, glycosuria, pyrexia, edema, and fatigue.

Adverse reactions reported during post-marketing experience include pancytopenia, hypersensitivity reaction, hepatic failure, leukocytoclastic vasculitis, urticaria, erythema multiforme, alopecia, acute renal failure, and tubulointerstitial nephritis, gallstones and related biliary disorders, elevations of liver transaminases, and hepatic failure. Any such adverse events will be recorded in the subject's Case Report Form (CRF).

Study design.

The study incorporates 4 arms, which will recruit in parallel:

Arm 1: (open, randomized, comparative) will consist of 10 patients with confirmed HC, who will be randomized to receive standard treatment with venesection (withdrawal of 450 mL blood every 8 to 10 days).

Arm 2: (open, randomized, comparative) will consist of 10 patients with confirmed HC, who will be randomized to receive investigational treatment with deferasirox (10 mg/kg orally given once daily) for a period of 12 months;

Arm 3: (open, non-comparative) will consist of 20 patients with confirmed MDS, all of whom will receive investigational treatment with deferasirox (initially 10 mg/kg orally given once daily, can be increased to max 40 mg/kg) for a period of 12 months;

Arm 4: will consist of 10 healthy volunteers who will undergo the same screening assessments (i.e. with respect to relevant exclusion criteria) and will act as non-treated normal controls for comparison of investigational blood tests.

The study will be non-blinded. Subjects and investigators will be aware of their subject and treatment arm.

Subjects will undergo assessments at screening (within 1-14 days prior to baseline), and for patients at baseline Day 0, and at 2,4,6,8 weeks, and thereafter monthly until 12 months, and at follow up 4-6 weeks after treatment has been completed. Healthy controls will be examined at screening, 2,6 and 12 months. Study-specific assessments will include physical examinations/vital signs, sampling of blood, urine, and for patients only: bone marrow and MRI to assess the effect of iron overload and iron reduction treatment on the following:

* Conventional tests to indicate iron overload: ferritin and transferrin saturation in serum; LIC and HIC, bone marrow iron content using microscopy.
* Hepcidin concentration in serum;
* NTBI concentration in serum;
* Intracellular signal transduction parameters: Analysis of the stress sensor p53, NFkB, and mTOR in leukocytes from peripheral blood;
* Trace metal concentrations in serum and urine;
* Antioxidant capability in blood hemolysate: Cu,Zn-SOD;
* Free radical damage to DNA and RNA: 8-oxodG concentration in urine;
* For MDS patients: number of transfusions;
* For HC and MDS patients: number of hospitalizations and overall survival;
* Safety and tolerability.

For patients and controls, samples of peripheral blood will be taken pre-dose, and at 24 hours after dosing, for assessment of stress sensor p53, NFkB, and mTOR.

Interim assessments. Routine blood and urine tests will be performed for patients at 2,4,6,8 weeks, and thereafter monthly until 12 months and at follow up 4-6 weeks after end of treatment for monitoring the disease, for safety reasons, and to obtain data for comparison traditional biomarkers with the new investigational biomarkers hepcidin and NTBI.

Volunteers will undergo all safety assessments plus investigational blood and urine tests. They will not undergo MRI, bone marrow examinations, registrations of transfusions, or active treatment with deferasirox or venesection.

Patients with HC or MDS will undergo a follow-up assessment 4 to 6 weeks after last dose. At this visit, all safety assessments and investigational blood and urine tests, including a pregnancy test, will be repeated, but MRI and bone marrow examination will not be performed. Volunteer controls will not attend for this visit.

This is an exploratory study with no sample size calculation and no minimum enrollment requirement. It is anticipated that a maximum of 40 patients will be enrolled in order to obtain at least 30 patients fulfilling the study criteria; 10 volunteers will also be enrolled.

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New Biomarkers.

Cu,Zn-Super Oxid Dismutase (SOD)is an antioxidant enzyme

Novartis

Haukeland University Hospital

Digestive System Diseases

Carcinoma

Liver Cirrhosis

Carcinoma, Hepatocellular

Fibrosis

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Anti-Infective Agents

Central Nervous System Depressants

Ethanol

Ultrasonographic screening

Jean-Claude Trinchet, Pr, MD, PhD

Liver carcinoma is becoming the main complication of cirrhosis. Treatment of symptomatic or large tumors is disappointing. Regular ultrasonographic screening of small (curable) tumors is currently recommended, but the best periodicity is unknown.This randomized trial is aimed to compare 6-month (current recommendation) and 3-month ultrasonographic screenings.

Patients: All consecutive patients with compensated HBV, HCV, alcohol or hemochromatosis-related cirrhosis (without any previous clinical complication including liver cancer).

Randomization: factorial: ultrasonography (3-month versus 6-month); serum alfa-fetoprotein assay (none versus 6-month).

End points: rate of small tumors (first main criteria); survival (second main criteria).

Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis

Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis. A Randomized Trial Comparing Two Periodicities of Ultrasonographic Surveillance: 3-month vs 6-month

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Massive Iron Deposit Assessment	NCT01572922	Iron Overload Excessive Body ...	R2-UTE R2-GRE Liver biopsy	-	St. Jude Children's Research Hospital
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome	NCT01892644	Hemochromatosis Myelodysplastic...	Deferasirox Venesection Deferasirox	18 Years - 80 Years	Haukeland University Hospital
Massive Iron Deposit Assessment	NCT01572922	Iron Overload Excessive Body ...	R2-UTE R2-GRE Liver biopsy	-	St. Jude Children's Research Hospital
Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis	NCT00190385	Compensated Cir...	Ultrasonographi...	30 Years - 75 Years	Assistance Publique - Hôpitaux de Paris
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome	NCT01892644	Hemochromatosis Myelodysplastic...	Deferasirox Venesection Deferasirox	18 Years - 80 Years	Haukeland University Hospital
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome	NCT01892644	Hemochromatosis Myelodysplastic...	Deferasirox Venesection Deferasirox	18 Years - 80 Years	Haukeland University Hospital

Spots Global Cancer Trial Database for hemochromatosis